The Great Debate: Should We Stent Vulnerable Plaques to Prevent Heart Attacks?
A pivotal debate in cardiology examines whether preventive percutaneous coronary intervention (PCI) should become the standard treatment for non-flow-limiting vulnerable plaques, a major source of acute coronary syndromes. Despite advances in lipid-lowering and anti-inflammatory therapies, residual cardiovascular risk persists, driving interest in sealing high-risk plaques identified by advanced intracoronary imaging. While the PREVENT trial suggested a reduction in composite outcomes like cardiac death and myocardial infarction with preventive PCI compared to optimal medical therapy alone, the benefits were primarily driven by softer endpoints. Significant reductions in hard outcomes like mortality were not observed, raising questions about procedural risks, cost-effectiveness, and the role of novel, intensive anticoagulation and lipid management strategies in this evolving clinical paradigm.
Study Significance: For hematologists focused on thrombosis and anticoagulation, this debate directly intersects with your expertise in managing clotting risks. The discussion underscores the complex interplay between plaque biology, procedural intervention, and systemic medical therapy, including the use of direct oral anticoagulants (DOACs). It highlights a critical frontier in personalized cardiovascular care where hematological management of coagulation must be integrated with interventional strategies to optimize patient outcomes and mitigate bleeding risks.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
